REFERENCES
1. Iliev ID, Ananthakrishnan AN, Guo CJ. Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities. Nat Rev Microbiol. 2025;23:509-24.
2. Caruso R, Lo BC, Chen GY, Núñez G. Host-pathobiont interactions in Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2025;22:395-414.
3. Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382-92.
4. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4:293-305.
5. Lloyd-Price J, Arze C, Ananthakrishnan AN, et al.; IBDMDB Investigators. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569:655-62.
6. Smillie CS, Biton M, Ordovas-Montanes J, et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell. 2019;178:714-730.e22.
7. Jaeger N, Gamini R, Cella M, et al. Single-cell analyses of Crohn’s disease tissues reveal intestinal intraepithelial T cells heterogeneity and altered subset distributions. Nat Commun. 2021;12:1921.
8. Neurath MF. Strategies for targeting cytokines in inflammatory bowel disease. Nat Rev Immunol. 2024;24:559-76.
9. Feagan BG, Rutgeerts P, Sands BE, et al.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699-710.
10. Sands BE, Sandborn WJ, Panaccione R, et al.; UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201-14.
11. Ariaee A, Koentgen S, Wardill HR, et al. Prebiotic selection influencing inflammatory bowel disease treatment outcomes: a review of the preclinical and clinical evidence. eGastroenterology. 2024;2:e100055.
12. Zhang Y, He J, Zeng H, Xu D, Li W, Wang Y. Advances in prebiotic carbohydrate-based targeted delivery: overcoming gastrointestinal challenges for bioactive ingredients. Food Chem. 2025;466:142210.
13. Zheng B, Wang L, Yi Y, Yin J, Liang A. Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease. Asian J Pharm Sci. 2024;19:100943.
14. Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14:491-502.
15. Loy L, Petronio L, Marcozzi G, Bezzio C, Armuzzi A. Dietary fiber in inflammatory bowel disease: are we ready to change the paradigm? Nutrients 2024;16:1108.
16. van Deuren T, Umanets A, Venema K, et al. Specific dietary fibers steer toward distal colonic saccharolytic fermentation using the microbiota of individuals with overweight/obesity. Food Res Int. 2025;209:116271.
17. De Vuyst L, Leroy F. Cross-feeding between bifidobacteria and butyrate-producing colon bacteria explains bifdobacterial competitiveness, butyrate production, and gas production. Int J Food Microbiol. 2011;149:73-80.
18. Ferreira-Lazarte A, Moreno FJ, Cueva C, Gil-Sánchez I, Villamiel M. Behaviour of citrus pectin during its gastrointestinal digestion and fermentation in a dynamic simulator (simgi®). Carbohydr Polym. 2019;207:382-90.
19. Ze X, Duncan SH, Louis P, Flint HJ. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon. ISME J. 2012;6:1535-43.
20. Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Waldron C, Schmidt TM. Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers. mBio. 2019;10.
21. Maathuis AJ, van den Heuvel EG, Schoterman MH, Venema K. Galacto-oligosaccharides have prebiotic activity in a dynamic in vitro colon model using a 13C-labeling technique. J Nutr. 2012;142:1205-12.
22. Zhao S, Lau R, Chen MH. Influence of chain length on the colonic fermentation of xylooligosaccharides. Carbohydr Polym. 2024;331:121869.
23. Zavadinack M, Cantu-Jungles TM, Abreu H, et al. (1 → 3), (1 → 6) and (1 → 3)-β-D-glucan physico-chemical features drive their fermentation profile by the human gut microbiota. Carbohydr Polym. 2024;327:121678.
24. Valcheva R, Koleva P, Martínez I, Walter J, Gänzle MG, Dieleman LA. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels. Gut Microbes. 2019;10:334-57.
25. Kennedy JM, De Silva A, Walton GE, Poveda C, Gibson GR. Comparison of prebiotic candidates in ulcerative colitis using an in vitro fermentation model. J Appl Microbiol. 2024;135:lxae034.
26. Wang Z, Gao M, Kan J, et al. Resistant starch from purple sweet potatoes alleviates dextran sulfate sodium-induced colitis through modulating the homeostasis of the gut microbiota. Foods. 2024;13:1028.
27. Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015;17:662-71.
28. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341:569-73.
29. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446-50.
30. Maghsoumi-Norouzabad L, Bagherzadeh-Karimi A, Aliakbari Majd S, Hosseini L, Shahi F. The effects of prebiotic dietary fibers, probiotics, and synbiotics on gut permeability and immunity: a systematic review. Iran J Med Sci. 2025;50:500-29.
31. Limketkai BN, Godoy-Brewer G, Shah ND, et al. Prebiotics for induction and maintenance of remission in inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2025;31:1220-30.
32. Zhou S, Wang M, Li W, et al. Comparative efficacy and tolerability of probiotic, prebiotic, and synbiotic formulations for adult patients with mild-moderate ulcerative colitis in an adjunctive therapy: a network meta-analysis. Clin Nutr. 2024;43:20-30.
33. Hang S, Paik D, Yao L, et al. Bile acid metabolites control T(H)17 and T(reg) cell differentiation. Nature. 2019;576:143-8.
34. Benjamin JL, Hedin CR, Koutsoumpas A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut. 2011;60:923-9.
35. Farjadian F, Ghasemi S, Akbarian M, Hoseini-Ghahfarokhi M, Moghoofei M, Doroudian M. Physically stimulus-responsive nanoparticles for therapy and diagnosis. Front Chem. 2022;10:952675.
36. Jiménez-Sánchez M, Pérez-Morales R, Goycoolea FM, et al. Self-assembled high molecular weight inulin nanoparticles: enzymatic synthesis, physicochemical and biological properties. Carbohydr Polym. 2019;215:160-9.
37. Joseph S, Jadav M, Solanki R, Patel S, Pooja D, Kulhari H. Synthesis, characterization, and application of honey stabilized inulin nanoparticles as colon targeting drug delivery carrier. Int J Biol Macromol. 2024;263:130274.
38. Seyam S, Choukaife H, Al Rahal O, Alfatama M. Colonic targeting insulin-loaded trimethyl chitosan nanoparticles coated pectin for oral delivery: in vitro and in vivo studies. Int J Biol Macromol. 2024;281:136549.
39. Mishra N, Pal S, Sharma M, et al. Crosslinked and PEGylated Pectin Chitosan nanoparticles for delivery of Phytic acid to colon. Int J Pharm. 2023;639:122937.
40. Licciardi M, Scialabba C, Sardo C, Cavallaro G, Giammona G. Amphiphilic inulin graft co-polymers as self-assembling micelles for doxorubicin delivery. J Mater Chem B. 2014;2:4262-71.
41. Sardo C, Auriemma G, Mazzacano C, et al. Inulin amphiphilic copolymer-based drug delivery: unraveling the structural features of graft constructs. Pharmaceutics. 2024;16:971.
42. Mandracchia D, Trapani A, Perteghella S, et al. pH-sensitive inulin-based nanomicelles for intestinal site-specific and controlled release of celecoxib. Carbohydr Polym. 2018;181:570-8.
43. Jing X, Li W, Gao Y, et al. Propyl inulin nanoprebiotics as a synbiotic partner of Lactiplantibacillus plantarum for Inhibiting pathogenic infection in a mouse model. Carbohydr Polym Technol Appl. 2025;10:100837.
44. Tao Y, Zheng D, Zhao J, et al. Self-assembling pH-responsive nanoparticle platform based on pectin-doxorubicin conjugates for codelivery of anticancer drugs. ACS Omega. 2021;6:9998-10004.
45. Gu X, Li W, Jiang X, Chang C, Wu J. Pectin-coated whey protein isolate/zein self-aggregated nanoparticles as curcumin delivery vehicles: effects of heating, pH, and adding sequence. Int J Biol Macromol. 2024;258:128892.
46. Su L, Zhao D, Huang Q, et al. Preparation of pectin-coated and chitosan-coated phenylethanoside liposomes: studies on characterization, stability, digestion and release behavior. Int J Biol Macromol. 2024;261:129442.
47. Zhang Y, Zhang X, Lv L, et al. Versatile inulin/trans-ferulic acid/silk sericin nanoparticles-nourished probiotic complex with prolonged intestinal retention for synergistic therapy of inflammatory bowel disease. Carbohydr Polym. 2025;350:123063.
48. Yan X, Diao M, Yu Y, et al. Characterization of resistant starch nanoparticles prepared via debranching and nanoprecipitation. Food Chem. 2022;369:130824.
49. Cheng X, Zheng X, Yang Y, et al. Multi-mode ultrasonic-driven self-assembly of banana-derived resistant starch nanoparticles for epigallocatechin gallate encapsulation and in vitro antiglycation evaluation. Int J Biol Macromol. 2026;377:153084.
50. Burapapadh K, Takeuchi H, Sriamornsak P. Novel pectin-based nanoparticles prepared from nanoemulsion templates for improving in vitro dissolution and in vivo absorption of poorly water-soluble drug. Eur J Pharm Biopharm. 2012;82:250-61.
51. Shih FY, Su IJ, Chu LL, et al. Development of pectin-type B gelatin polyelectrolyte complex for curcumin delivery in anticancer therapy. Int J Mol Sci. 2018;19:3625.
52. Jin MY, Yu SY, Wang EF, et al. Curcumin-loaded lactoferrin/pectin core-shell structured microgel nanoparticles: dual regulatory effects in alleviating inflammatory bowel disease. Nutrients. 2026;18:921.
53. Lee JH, Reischl S, Walter RL, et al. Orally delivered biodegradable targeted inflammation resolving pectin-coated nanoparticles induce anastomotic healing post intestinal surgery. Sci Rep. 2024;14:29253.
54. Cao L, Peng J, Duan D, et al. Colon enzyme-activated prebiotic nanomedicine for targeted therapy of inflammatory bowel disease. Small Methods. 2026;10:e2401408.
55. Zhang X, Gao X, Yi X, et al. Multi-targeting inulin-based nanoparticles with cannabidiol for effective prevention of ulcerative colitis. Mater Today Bio. 2024;25:100965.
56. Li L, Liu J, Shi X, et al. Inulin-armored hesperetin‑zinc nanodrugs for synergistic redox-immune modulation and barrier repair in ulcerative colitis. Int J Biol Macromol. 2026;361:152088.
57. Zheng Y, Huang Y, Chen X, et al. Novel oat β-glucan nanoparticles for diabetes-associated colitis therapy. Mater Today Bio. 2026;36:102673.
58. Park N, Lee B, Jeon HJ, et al. Inulin-butyrate nanogel for modulation of gut microbiome, intestinal barrier, and regulatory T-cells in colitis. Small. 2026;22:e13252.
59. Yu L, Zhang H, Shi C, et al. Targeted intestinal barrier repair via probiotic-derived engineered outer membrane vesicles: a 3A1M strategy with antioxidant, anti-inflammatory, anti-ferroptotic, and microbiome modulation effects. Acta Pharm Sin B. 2026;16:2527-52.
60. Li S, Zhang P, Li Y, Zhao M, Deng H. Interface-engineered oral hybrid nanotherapeutics combining cerium nanozymes and extracellular vesicles for multimodal regulation of inflammatory bowel disease. ACS Appl Mater Interfaces. 2026;18:10416-27.
61. Yang F, Su Y, Yan C, Chen T, Cheung PCK. Attenuation of inflammatory bowel disease by oral administration of mucoadhesive polydopamine-coated yeast β-glucan via ROS scavenging and gut microbiota regulation. J Nanobiotechnol. 2024;22:166.
62. Li X, Cao L, Li J, et al. Orally Administrated inulin-modified nanozymes for CT-guided IBD theranostics. Int J Nanomedicine. 2025;20:2119-31.
63. Wang J, Wang Y, Zhu M, et al. Nanogel-coated nanozymes for ulcerative colitis targeted treatment by restoring redox homeostasis and anti-inflammatory activity. Colloids Surf B Biointerfaces. 2026;266:115845.
64. Zhang J, Zhao L, Liang A, et al. Resistant starch grafted cerium-sulfasalazine infinite coordination polymers synergistically remold intestinal metabolic microenvironment for inflammatory bowel disease therapy. J Nanobiotechnol. 2024;22:785.
65. Jin T, Lu H, Zhou Q, et al. H2S-releasing versatile montmorillonite nanoformulation trilogically renovates the gut microenvironment for inflammatory bowel disease modulation. Adv Sci (Weinh). 2024;11:e2308092.
66. Xu C, Su M, Xu M, et al. An oral dual-targeting inulin-based nanomicelle for ulcerative colitis therapy via combined H2S-mediated immunomodulation with prebiotic microbiota regulation. Nano Today. 2026;69:103055.
67. Li H, Cheng Y, Cui L, et al. Combining gut microbiota modulation and enzymatic-triggered colonic delivery by prebiotic nanoparticles improves mouse colitis therapy. Biomater Res. 2024;28:0062.
68. Zhang J, Zhang Y, Lu X, et al. Colon-targeted microbiota-modulating nanoparticles amplify azathioprine efficacy via gut microbiota axis remodeling in inflammatory bowel disease. J Nanobiotechnol. 2026;24.
69. Xian J, Zhong X, Gu H, et al. Colonic delivery of celastrol-loaded layer-by-layer liposomes with pectin/trimethylated chitosan coating to enhance its anti-ulcerative colitis effects. Pharmaceutics. 2021;13:2005.
70. Casellas F, Borruel N, Torrejón A, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther. 2007;25:1061-7.
